Top studies relevant to allergists from American Academy of Dermatology Annual Meeting

Interested in allergy-specific content from the American Academy of Dermatology Annual Meeting but could not attend in person? Healio presents this list of meeting coverage that might be relevant to your allergy/immunology practice.

Anti-CCR4 inhibitor shows promise in atopic dermatitis

Patients with atopic dermatitis treated with RPT193 (RAPT Therapeutics), an oral CCR4 inhibitor, showed improvement in disease severity, as well as down-regulation of AD genes, according to results of a small phase 1b study. Read more.

VIDEO: Dupixent in development for multiple inflammatory diseases

In this video, Naimish Patel, MD, head of global development, immunology and inflammation at Sanofi, discusses research regarding dupilumab (Dupixent, Sanofi/Regeneron) presented at the meeting. Watch here.

Pruritus, atopic dermatitis gene expression downregulated by difelikefalin treatment

Pruritus and AD-related gene expression were altered after treatment with difelikefalin (Korsuva, Vifor Pharma), a novel oral kappa opioid receptor agonist, according to results of a phase 2 study. Read more.

Chronic spontaneous urticaria negatively impacts life, work

Chronic spontaneous urticaria showed a negative impact on patients’ lives, including on both mental and physical health and daily activities, according to survey results of 635 patients. Read more.

Long-term tralokinumab maintains safety, efficacy in atopic dermatitis

Long-term use of tralokinumab (Adbry, LEO Pharma), a selective interleukin-13 inhibitor, showed sustained AD improvement with no new safety signals, according to a 3.5-year interim safety analysis of the long-term, open-label extension ECZTEND trial, which included 1,442 patients with moderate to severe disease. Read more.